SpiroChem AG:
Rosental area, WRO-1047-3
Mattenstrasse 22
4058 Basel, Switzerland


Tel: + 41 61 685 95 00
E-mail: contact@spirochem.com


icon

Swiss Discovery Sciences

Search by SPC, Chemical Name, CAS or keyword

SpiroChem @ 4 major European events in March
Mar 2024

Conferences

SpiroChem @ 4 major European events in March


Discover the four major events SpiroChem representatives will be attending in March. Simply get in touch with us and arrange a meeting. Together, let's delve into your project requirements and explore all development opportunities. We look forward to hearing from you and discussing advances in the field of drug discovery.

9th RSC-BMCS Fragment-based Drug Discovery Meeting

Join us at the 9th RSC-BMCS Fragment-based Drug Discovery meeting! Explore case studies in Fragment-based Drug Discovery that have delivered compounds to late stage medicinal chemistry, preclinical or clinical programmes. Witness advancements in screening technologies like high concentration, NMR, SPR, and X-ray.

Thomas Fessard, PhD – CEO
Gerhard Müller, PhD – CSO
Raquel Mato, PhD – Research Chemist

14th World ADC Europe 2024

Experience the surge of antibody-drug conjugates! Witness milestones like ENHERTU's success, Pfizer's $43B acquisition of Seagen, and FDA approval for ELAHERE. Join us at 14th World ADC London to explore monumental wins, reflect on ongoing challenges, and collaborate on innovative ADC development strategies.

Florent Beaufils, PhD – COO

Frontiers in Medicinal Chemistry

Meet us at the international symposium focusing on current developments, novel approaches and cutting-edge technologies in the field of medicinal chemistry and drug research. The program features lectures and poster presentations, aiming for scientific excellence and attracting both industrial and academic scientists in related fields.

Benoit Carbain, PhD – Research Chemist
Sylvain Blanc, PhD – Research Chemist

4th TPD Summit Europe

The 4th TPD Summit Europe is back as the leading forum for Targeted Protein Degradation experts. Explore novel degrader development, address safety concerns, and discover molecular glues to deliver approved degraders to high-value targets and patients in need. Topics range from hit finding, validation, and lead optimisation, to assessing DMPK profiles.

Laurence Jung, PhD – BD Manager


Reach out to arrange a meeting to discuss current hot topics in the field of drug discovery.

Contact us for more details

Newsletter

Don’t miss out on what is important.

Let us inspire you. Subscribe now to keep updated on new concepts, products, solutions & more.